Highlights Cohort 2 completed in participants with neuroblastoma who received therapy with 67Cu SARTATE™ at a dose of 175MBq/kg body weight No Dose Limiting.
Share:
SYDNEY, Dec. 15, 2020 /PRNewswire/ Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has completed a capital raising of $25,000,410.
Dr Alan Taylor, Executive Chairman of Clarity Pharmaceuticals, commented, It has been a pivotal year for Clarity with numerous critical milestones achieved in the development of our main products, advancement of our platform, as well as accelerated corporate and strategic activities despite facing an unprecedented global environment. The money raised will enable us to keep the momentum from 2020 going and provide financial resources to progress the following important initiatives: